{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:35:11Z","timestamp":1760236511997,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T00:00:00Z","timestamp":1638057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Apremilast (Otezla\u00ae) is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et\u2019s disease. While PDE4 inhibition overall is mechanistically understood, the effect of apremilast on the innate immune response, particularly inflammasome activation, remains unknown. Here, we assessed the effect of apremilast in a psoriasis mouse model and primary human cells. Psoriatic lesion development in vivo was studied in K5.Stat3C transgenic mice treated with apremilast for 2 weeks, resulting in a moderate (2 mg\/kg\/day) to significant (6 mg\/kg\/day) resolution of inflamed plaques after 2-week treatment. Concomitantly, epidermal thickness dramatically decreased, the cutaneous immune cell infiltrate was reduced, and proinflammatory cytokines were significantly downregulated. Additionally, apremilast significantly inhibited lipopolysaccharide- or anti-CD3-induced expression of proinflammatory cytokines in peripheral mononuclear cells (PBMCs). Notably, inflammasome activation and secretion of IL-1\u03b2 were not inhibited by apremilast in PBMCs and in human primary keratinocytes. Collectively, apremilast effectively alleviated the psoriatic phenotype of K5.Stat3 transgenic mice, further substantiating PDE4 inhibitor-efficiency in targeting key clinical, histopathological and inflammatory features of psoriasis. Despite lacking direct effect on inflammasome activation, reduced priming of inflammasome components upon apremilast treatment reflected the indirect benefit of PDE4 inhibition in reducing inflammation.<\/jats:p>","DOI":"10.3390\/ijms222312878","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T23:22:28Z","timestamp":1638314548000},"page":"12878","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1\u03b2 Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-5066","authenticated-orcid":false,"given":"Barbara","family":"Meier-Schiesser","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Raemistrasse 100, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-167X","authenticated-orcid":false,"given":"Mark","family":"Mellett","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Raemistrasse 100, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marigdalia K.","family":"Ramirez-Fort","sequence":"additional","affiliation":[{"name":"BioFort, P.O. Box 1374, Guaynabo, PR 00970, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia-Tatjana","family":"Maul","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Raemistrasse 100, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Klug","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Raemistrasse 100, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Winkelbeiner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Raemistrasse 100, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-936X","authenticated-orcid":false,"given":"Gabriele","family":"Fenini","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Raemistrasse 100, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schafer","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, 100 Nassau Park Blvd #300, Princeton, NJ 08540, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Contassot","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Dermatology Department, Basel University Hospital, University of Basel, Hebelstrasse 20, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ludwigs-Maximilians-University, Frauenlobstra\u00dfe 9-11, 80337 Munich, Germany"},{"name":"Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, 1600 NW 10th Avenue, Miami, FL 33136, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2340\/00015555-0770","article-title":"Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany","volume":"90","author":"Augustin","year":"2010","journal-title":"Acta. Derm. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jaad.2005.10.057","article-title":"Innate and adaptive immunity and the pathophysiology of psoriasis","volume":"54","author":"Gaspari","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","first-page":"S63","article-title":"Continuous versus intermittent therapy for moderate-to-severe psoriasis","volume":"31","author":"Levin","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_4","first-page":"345","article-title":"Narrowband UVB phototherapy for the treatment of psoriasis: A review and update","volume":"68","author":"Barbagallo","year":"2001","journal-title":"Cutis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"208","article-title":"Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics","volume":"25","author":"Nyfors","year":"1978","journal-title":"Dan. Med. Bull."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0190-9622(94)70121-0","article-title":"Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients","volume":"30","author":"Altmeyer","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s001050050401","article-title":"Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients","volume":"47","author":"Altmeyer","year":"1996","journal-title":"Hautarzt"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000063148","article-title":"Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris","volume":"205","author":"Gollnick","year":"2002","journal-title":"Dermatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_11","first-page":"821","article-title":"Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials","volume":"14","author":"Gottlieb","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014Results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/bjd.17454","article-title":"Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: A pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies","volume":"180","author":"Reich","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_14","first-page":"1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0140-6736(07)61129-5","article-title":"Current and future management of psoriasis","volume":"370","author":"Menter","year":"2007","journal-title":"Lancet"},{"key":"ref_17","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"ref_18","unstructured":"Characteristics, E.S.o.P. (2021, September 12). FDA Label Reference ID: 4464834, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/205437Orig1s007lbl.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.cub.2007.05.074","article-title":"The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes","volume":"17","author":"Feldmeyer","year":"2007","journal-title":"Curr. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/13543770903313753","article-title":"PDE4 inhibitors: A review of current developments (2005\u20132009)","volume":"19","author":"Pages","year":"2009","journal-title":"Expert opin. Ther. Pat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling","volume":"76","author":"Conti","year":"2007","journal-title":"Annu. Rev. Biochem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Lebwohl","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of Apremilast for Oral Ulcers in Behcet\u2019s Syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature11588","article-title":"The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP","volume":"492","author":"Lee","year":"2012","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","article-title":"Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease.","volume":"27","author":"Masters","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.4049\/jimmunol.1401343","article-title":"Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages","volume":"194","author":"Sokolowska","year":"2015","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jid.2018.07.025","article-title":"A Critical Role of the IL-1beta-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis","volume":"139","author":"Cai","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cei.13370","article-title":"Evidence for a role of autoinflammation in early-phase psoriasis","volume":"198","author":"Fanoni","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nm1162","article-title":"Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model","volume":"11","author":"Sano","year":"2005","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Danis, J., and Mellett, M. (2021). Nod-Like Receptors in Host Defence and Disease at the Epidermal Barrier. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094677"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2016.02.1164","article-title":"Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis","volume":"75","author":"Bissonnette","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/bph.14667","article-title":"Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity","volume":"176","author":"Li","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jid.2017.10.013","article-title":"Research Techniques Made Simple: Murine Models of Human Psoriasis","volume":"138","author":"Hawkes","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13395-017-0121-2","article-title":"Inhibition of Stat3 signaling ameliorates atrophy of the soleus muscles in mice lacking the vitamin D receptor","volume":"7","author":"Gopinath","year":"2017","journal-title":"Skelet. Muscle"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1111\/jdv.12736","article-title":"Immunohistochemical expression of VDR is associated with reduced integrity of tight junction complex in psoriatic skin","volume":"29","author":"Visconti","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_40","first-page":"7509","article-title":"Vitamin D receptor regulates high-level glucose induced retinal ganglion cell damage through STAT3 pathway","volume":"22","author":"Lei","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.123390","article-title":"Disrupting the IL-36 and IL-23\/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis","volume":"4","author":"German","year":"2019","journal-title":"JCI Insight"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/906349","article-title":"The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: Substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1)","volume":"2015","author":"Schafer","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","article-title":"Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex","volume":"28","author":"Schafer","year":"2016","journal-title":"Cell Signal."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/23\/12878\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:37:02Z","timestamp":1760168222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/23\/12878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,28]]},"references-count":43,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["ijms222312878"],"URL":"https:\/\/doi.org\/10.3390\/ijms222312878","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,11,28]]}}}